ClinicalTrialsFinder

High Grade Neuroendocrine Cancer Clinical Trials in Los Angeles, California

1 recruitingLos Angeles, California

Showing 1–1 of 1 trials

Recruiting
Phase 1

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198